CGEM NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Cullinan Oncology LLC · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 16.50 USD
-3.5% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 14.4% above the Trend Line and sits at 78.7% of its 52-week range. The latest completed week returned -3.5%, after a -6.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 53/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 56 out of 100
Latest Close 16.50 USD 31 Jul 2026
1W Return -3.5% latest completed week
4W Return -6.4% short-term follow-through
12W Return 13.4% quarterly tape
Trend Breadth 69.2% 36 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • The trend backdrop is active with a 36-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.5% Latest completed week; four-week move -6.4%. Indicator stack 83/59 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 53/100 conviction; expected move 24.4%. News sentiment 56/100 53 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 14.4% above the Trend Line and sits at 78.7% of its 52-week range. The latest completed week returned -3.5%, after a -6.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8512-week average 0.72

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.85Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.4% over four weeks, 13.4% over 12 weeks, and 115.1% over one year. The current trend has remained active for 36 consecutive weeks.

Performance by holding period

1W-3.5%
4W-6.4%
12W13.4%
26W38.0%
52W115.1%
Active trend streak36 weeks
Active weeks in one year36
Trend breadth69.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.41Latest activity-pressure read.
Pressure change16.4%Four-week change in activity pressure.
Leadership29.26Latest relative-leadership reading.
RS change-26.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value57/100Relative valuation strength. Underlying universe rank 44; rank 1 is best.
Quality55/100Profitability and accounting quality. Underlying universe rank 46; rank 1 is best.
Momentum57/100Medium-term price momentum. Underlying universe rank 44; rank 1 is best.
Growth57/100Revenue and earnings growth. Underlying universe rank 44; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-14.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-56.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CGEM shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.48, expected move of 24.4%, and Sharemaestro trend signal active.

Conviction53/100
Expected move24.4%
Put/call volume0.48
Pressure36
Speculation46
Volatility96
Trend agreement71
Open options detail
Insider activity10 / 5

10 acquisitions and 5 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 53 relevant articles.

18 positive · 34 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move24.4%Nearest-chain priced movement where available.
52-week drawdown-15.1%Distance below the 52-week high.
13-week volatility10.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+22.4%Week of 26 Jun.
Worst week-17.8%Week of 5 Jun.
Latest week-3.5%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains8
Flat weeks0
Modest losses3
Sharp losses7
Recent vol10.9%13-week weekly-return volatility.
Base vol10.5%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew9.8% / -7.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape61/100

Trend, activity pressure, participation, and risk combine to a 61/100 tape read.

 Indicator analysis82/100

Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 12/12.

Activity pressure 0.85; No reversal markers Factors58/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 47; Small Cap Core rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options56/100

CGEM shows volatility options pressure with a 53/100 conviction score, put-call volume ratio of 0.48, expected move of 24.4%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 24.4% Sentiment56/100

Weighted news tone is neutral across 53 relevant articles.

Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday Insiders10 / 5

10 acquisitions and 5 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202616.50 USD-3.5%14.43 USD12.69 USD0.4129.263.0MOn
24 Jul 202617.10 USD-3.3%14.21 USD12.65 USD0.4936.122.1MOn
17 Jul 202617.69 USD-2.4%13.99 USD12.60 USD0.7040.113.2MOn
10 Jul 202618.13 USD2.8%13.72 USD12.56 USD0.6139.393.2MOn
3 Jul 202617.63 USD-4.2%13.52 USD12.52 USD0.3539.663.4MOn
26 Jun 202618.40 USD22.4%13.28 USD12.47 USD0.0648.738.9MOn
19 Jun 202615.03 USD9.7%13.05 USD12.42 USD-0.1217.557.5MOn
12 Jun 202613.70 USD1.4%12.86 USD12.40 USD-0.2110.717.8MOn
5 Jun 202613.51 USD-17.8%12.69 USD12.40 USD0.0412.034.9MOn
29 May 202616.44 USD18.8%12.48 USD12.40 USD0.2730.475.0MOn
22 May 202613.84 USD-12.0%12.22 USD12.36 USD-0.0313.735.3MOn
15 May 202615.73 USD8.1%12.02 USD12.34 USD-0.1231.415.3MOn
8 May 202614.55 USD8.3%11.75 USD12.29 USD-0.0322.245.9MOn
1 May 202613.43 USD1.6%11.52 USD12.26 USD0.0719.712.8MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.